<DOC>
	<DOCNO>NCT00688740</DOCNO>
	<brief_summary>The purpose study compare disease-free survival treatment docetaxel combination doxorubicin cyclophosphamide 5-fluorouracil combination doxorubicin cyclophosphamide operable breast cancer patient positive axillary lymph node .</brief_summary>
	<brief_title>Docetaxel Node Positive Adjuvant Breast Cancer</brief_title>
	<detailed_description>In addition 5-year analysis conduct September 2003 , two analysis plan 590 700 Disease Free Survival event occur . However , due low predict DFS event rate , agreement FDA EMA , time-based final analysis 10 year consider appropriate event-based ( 700 Disease Free Survival event ) analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically prove breast cancer ( invasive adenocarcinoma least one axillary lymph node show evidence tumor among minimum six resect lymph node ) . Definitive surgical treatment must either mastectomy , breast conserving surgery axillary lymph node dissection operable breast cancer . Margins resect specimen definitive surgery must histologically free invasive adenocarcinoma ductal carcinoma . Exclusion criterion : Prior systemic anticancer therapy breast cancer ( immunotherapy , hormonotherapy , chemotherapy ) . Prior anthracycline therapy taxoids ( paclitaxel , docetaxel ) malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>adjuvant treatment</keyword>
</DOC>